In Conversation: Rodeina Challand, VP Scientific Affairs, BioFactura

From BioBuzz by Workforce Genetics
By Steven Surdez 12AUG2022

A key recent hire for BioFactura was biosimilars and scientific affairs expert Rodeina Challand, who joined the team as its new VP of Scientific Affairs in late 2021. We caught up with Challand to discuss her background, the biosimilars market landscape, and why she’s excited about what’s next for BioFactura…

<Read Full Article>

August 12, 2022 BioFactura In The News

About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.